Related Experiment Videos
[Expression of EGF receptor subfamily in tumor]
Abstract:
The members of EGF receptor subfamily are transmembrane glycoproteins with tyrosine kinase activity. Once EGF or EGF-related peptides binds to the receptors, they undergo autophosphorylation and binding to the SH2 protein, which in turn activates the intracellular signaling cascade. In the squamous carcinoma of head and neck, esophagus and lung, the EGF receptor gene amplification and EGF receptor hyperproduction are frequently observed. In the adenocarcinoma of pancreas, breast and stomach, hyperproduction of the EGF receptor subfamily is common, suggesting the involvement of these growth factor receptors in the tumorigenesis. The prognostic value of EGF receptor hyperproduction appears considerable when combined with other factors. EGF receptor subfamily members are useful targets for the immunotoxin therapy and immunogene therapy.
Insights
Epidermal Growth Factor (EGF) receptor hyperproduction is common in various cancers, indicating its role in tumor development. This receptor subfamily shows promise as a therapeutic target for cancer treatment.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Epidermal Growth Factor (EGF) receptor subfamily members are transmembrane glycoproteins possessing tyrosine kinase activity.
- Ligand binding triggers receptor autophosphorylation and SH2 protein interaction, initiating intracellular signaling cascades.
Purpose of the Study:
- To investigate the role of EGF receptor subfamily hyperproduction in tumorigenesis.
- To explore the prognostic value of EGF receptor hyperproduction in various cancers.
- To assess the potential of EGF receptor subfamily members as therapeutic targets.
Main Methods:
- Analysis of EGF receptor gene amplification and hyperproduction in cancer tissues.
- Correlation of EGF receptor hyperproduction with clinical factors for prognostic assessment.
- Evaluation of EGF receptor subfamily members as targets for immunotoxin and immunogene therapy.
Main Results:
- Frequent EGF receptor gene amplification and hyperproduction observed in squamous cell carcinomas of the head and neck, esophagus, and lung.
- Common hyperproduction of the EGF receptor subfamily in adenocarcinomas of the pancreas, breast, and stomach.
- Significant prognostic value of EGF receptor hyperproduction when considered with other factors.
Conclusions:
- EGF receptor subfamily hyperproduction is implicated in the tumorigenesis of multiple cancer types.
- EGF receptor subfamily members represent viable targets for novel immunotherapies.
- Further research into EGF receptor-targeted therapies is warranted.